| Literature DB >> 29428669 |
Bing-Ya Yang1, Jing-Wei Song2, Hong-Zhi Sun2, Ji-Cheng Xing3, Zhi-Hui Yang3, Chang-Yong Wei4, Tuo-Ye Xu5, Zhen-Nan Yu5, Ye-Nan Zhang2, Ying-Fan Wang2, Hao Chang2, Zhi-Peng Xu1, Min Hou2, Min-Jun Ji6, Yan-Song Zhang5.
Abstract
Glioma has been considered as one of the most aggressive and popular brain tumors of patients. It is essential to explore the mechanism of glioma. In this study, we established PSMB8 as a therapeutic target for glioma treatment. Expression of PSMB8 as well as Ki-67 was higher in glioma tissues demonstrated by western blot and immunohistochemistry. Then, the role of PSMB8 in migration and proliferation of glioma cells was investigated by conducting wound-healing, trans-well assay, cell counting kit (CCK)-8, flow cytometry assay and colony formation analysis. The data showed that interfering PSMB8 may inhibit the migration and proliferation of glioma cells by reducing expression of cyclin A, cyclin B1, cyclin D1, Vimentin, and N-cadherin, and by increasing expression of E-cadherin. Additionally, interfering PSMB8 may induce apoptosis of glioma cells by upregulating caspase-3 expression. Furthermore, these in vitro findings were validated in vivo and the ERK1/2 and PI3k/AKT signaling pathways were involved in PSMB8-triggered migration and proliferation of glioma cells. In an in vivo model, downregulation of PSMB8 suppressed tumor growth. In conclusion, PSMB8 is closely associated with migration, proliferation, and apoptosis of glioma cells, and might be considered as a novel prognostic indicator in patients with gliomas.Entities:
Keywords: AKT; ERK1/2; Glioma; PSMB8
Mesh:
Substances:
Year: 2018 PMID: 29428669 DOI: 10.1016/j.biopha.2018.01.170
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529